8-KLeadership ChangesRegulation FDExhibits & Filings

CARDINAL HEALTH INC 8-K Report, Executive Changes (Mar 10, 2025)

Filed March 10, 2025For Securities:CAH

Summary

Cardinal Health, Inc. (CAH) announced a significant expansion of its Board of Directors with the immediate election of two new independent directors, Robert W. Musslewhite and Sudhakar Ramakrishna, effective March 7, 2025. Both individuals bring extensive leadership experience from the technology and healthcare sectors. Mr. Musslewhite, former CEO of Definitive Healthcare Corp., and Mr. Ramakrishna, CEO of SolarWinds Corporation, have been appointed to key board committees, including Audit, Human Resources and Compensation, and Risk Oversight. Their appointments are expected to enhance the board's expertise and strategic oversight.

Key Highlights

  • 1Two new independent directors, Robert W. Musslewhite and Sudhakar Ramakrishna, have been elected to the Board.
  • 2Both new directors bring significant executive leadership experience from technology and healthcare intelligence companies.
  • 3Mr. Musslewhite has been appointed to the Audit and Human Resources and Compensation Committees.
  • 4Mr. Ramakrishna has been appointed to the Audit and Risk Oversight Committees.
  • 5The new directors are considered independent under NYSE and SEC rules.
  • 6Appointments are effective immediately and directors will serve until the 2025 annual meeting.
  • 7The company issued a press release on March 10, 2025, to announce these appointments.

Frequently Asked Questions

Robert W. Musslewhite, former CEO of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and CEO of SolarWinds Corporation, have been elected to the Board of Directors.

Mr. Musslewhite will serve on the Audit and Human Resources and Compensation Committees. Mr. Ramakrishna will serve on the Audit and Risk Oversight Committees.

Yes, the Board has affirmatively determined that both Mr. Musslewhite and Mr. Ramakrishna are independent under the rules of the New York Stock Exchange and relevant SEC regulations.

The new directors will receive compensation consistent with that of other non-employee directors, as detailed in the Company's 2024 proxy statement.